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Abstract
Objective The aim of this study was to delineate the mechanisms of action of the plant Eucalyptus 
citriodora used traditionally for the treatment of type 2 diabetes.
Methods Insulin secretion and signal transduction were measured using clonal pancreatic β-cells 
and mouse islets. Glucose uptake was assessed using 3T3-L1 adipocytes and in vitro systems as-
sessed additional glucose-lowering actions. High-fat-fed (HFF) obese rats were used for in vivo 
evaluation and phytoconstituents were identified by RP-HPLC followed by LC-MS.
Key findings Eucalyptus citriodora stimulated 1.2–4.6-fold insulin release that was inhibited by 
the Ca2+-channel blocker, verapamil, KATP-channel opener, diazoxide and Ca
2+ free conditions. The 
effect was potentiated by IBMX and preserved in presence of tolbutamide or 30 mM KCl. The action 
mechanism involved membrane depolarization and elevation of intracellular Ca2+. Eucalyptus 
citriodora also significantly increased glucose uptake by 3T3-L1 cells and inhibited digestion of 
starch, glucose absorption, DPP-IV enzyme and glycation of protein. Administration of E. citriodora 
(250  mg/5  ml/kg) for 9  days to HFF obese-diabetic rats improved glycaemic control and β-cell 
function. The isolated phytoconstituents responsible for the β-cell actions included quercitrin, 
isoquercitrin and rhodomyrtosone E.
Conclusions Eucalyptus citriodora improves glycaemic control via multiple mechanisms. Further 
studies are required to assess the utility of the plant or active constituents in the therapy of type 
2 diabetes.
Keywords: insulin; glucose, type 2 diabetes; DPP-IV; phytomolecules
Introduction
Diabetes mellitus incidence is increasing globally due to obesity and 
increasingly unhealthy lifestyle.[1] The WHO identified the diabetes 
as the fastest growing metabolic disorder that has two major class 
namely type 1 and type 2 diabetes. Type 1 diabetes is a result of β-cell 
destruction, whereas type 2 diabetes is due to β-cell dysfunction and 
insulin resistance.[2] A report from International Diabetes Federation 
says that one in every 11 adults worldwide has type 2 diabetes.[3] It 
is expected that approximately 90% of diabetes patients have type 
2 diabetes, which causes secondary complications over time such 
as cardiovascular disease, retinopathy, cognitive decline and end-
stage renal disease.[4] The most common treatment options for type 
2 diabetes are diet, weight loss and use of either single or multiple 
oral anti-hyperglycaemic agents. These currently include metformin, 
sulphonylureas, meglitinides, thiazolidenediones, DPP-IV inhibi-
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action, stimulate insulin secretion or promote glucose excretion.[5] In 
poorly controlled cases insulin is also prescribed, but none of these 
interventions cure diabetes and most of these are expensive and 
often associated with secondary toxicities.[6] A meta-analysis showed 
that since 2012 prevalence of diabetes has increased by 11%, while 
cost per patients has increased by 13%, excluding the treatment of 
diabetic complications.[7] Medicinal plants and their phytochemicals 
have been known for many years to possess important pharmaco-
logical and biological actions.[8] In this respect, a large number of 
readily available and inexpensive plants have been used traditionally 
for treatment of obesity and diabetes and which continues today in 
many poorer and more remote societies.[9, 10]
Eucalyptus citriodora is a member of Myrtaceae family, and 
commonly known as lemon-scented gum, blue spotted gum or 
lemon eucalyptus. Eucalyptus citriodora has many traditional and 
pharmacological applications such as an analgesic, anti-inflam-
matory, and antipyretic remedy, and as an aid against respiratory 
infections and sinus congestion.[11] It is well known for containing 
important essential oils such as cineole, citronellal and citronellic 
acid.[12] The production of cytokines and chemokines such as 
TNF-a, IL-1β, leukotriene B4 and thromboxane B2 in inflamma-
tory cells has been shown to be inhibited by eucalyptol.[13, 14] The 
essential oils also have potential antioxidant and inhibitory ef-
fects against a wide range of microorganisms such as bacteria, 
fungi and yeasts.[15, 16]
In addition to its use as traditional medicine for diabetes, 
E. citriodora has been shown to counter hyperglycaemia in alloxan-
induced diabetic rats.[10] The leaves of this plant contain betulinic 
acid and corosolic acid which have been suggested to stimulate 
GLUT-4 translocation,[17] but the precise mechanisms responsible 
for the glucose-lowering actions are unknown. We hypothesized 
that phytochemicals present in E.  citriodora exert a spectrum of 
anti-diabetic activities mediated through diverse mechanisms. 
This study was therefore sought to assess, for the first time, the 
various molecular pathways and phytochemicals underlying the 
antidiabetic actions of E. citriodora using a number of in vitro and 
in vivo models.
Materials and Methods
Collecting and preparing crude extract
Eucalyptus citriodora leaves were purchased as powdered form (bo-
tanical accession number 43755)  from Jahangirnagar University, 
Dhaka, Bangladesh and extraction procedure was followed as per 
previous description.[18] Twenty-five grams of powdered leaf was 
dissolved into 1 l water and heated to boil. It was filtered using 
Whatman no. 1 filter paper and the sticky residue was then vacuum 
dried (Savant Speed vac, New York, NY, USA). Finally, gummy 
greenish residue obtained, was preserved at 4°C before analysis.
In vitro insulin-releasing studies
The clonal BRIN-BD11 cells[19] and isolated mouse islets[20] were 
used to test insulin-releasing effect. Leaf extract or purified HPLC 
fractions were incubated with or without known modulators of 
insulin secretion at different glucose concentrations (1.1, 5.6 or 
16.7  mM). Non-stimulatory, basal and stimulatory glucose levels 
were described as 1.1, 5.6 and 16.7  mM, respectively. The super-
natant samples were preserved at −20°C for insulin radioimmuno-
assay.[21] Insulin content from islets was measured by acid-ethanol 
extraction method.[22]
Membrane potential and intracellular calcium 
([Ca2+]i) concentration
Both membrane potential and intracellular [Ca2+]i concentrations 
of BRIN-BD11 cells in the presence of E. citriodora were measured 
by a FLIPR Membrane Potential and Calcium Assay Kit (Molecular 
Devices, Sunnyvale, CA, USA).[23]
Glucose uptake
The 3T3L1 differentiated cells were used as stated earlier.[24] 
Differentiated cells were treated with plant extract or 100 nM in-
sulin at 37°C for 30  min. Then, 2-NBDG (50  nM) was extended 
for 5 min. With ice-cold PBS, the wells were rinsed and each slide 
was fixed with three to four cover slips. Images were taken using 
microscopy at 10× magnification, and the intensity of fluorescence 
was calculated.
Glycation of insulin
The in vitro protein glycation was followed according to previous de-
scription.[25] Human insulin (1 mg/ml) and sodium cyanoborohydride 
(85.3 mg/ml) were incubated with D-glucose solution (246.5 mM) 
with (E.  citriodora) or without (control) treatment. The mixtures 
were incubated for 24 h at 37°C; finally, the reaction was stopped 
by 0.5M acetic acid. RP-HPLC was used to measure glycated and 
non-glycated insulin.[26] Positive control, aminoguanidine, a known 
inhibitor of protein glycation, was used.
DPP-IV enzyme activity in vitro
A fluorometric method was implied to determine DPP-IV enzyme 
activity as described previously.[27] An assay was performed using 
DPP-IV enzyme (8 mU/ml) and 200 µM of substrate (Gly-Pro-AMC) 
in a 96-well plates (Greiner). The fluorescence intensity was calcu-
lated with excitation and emission at 370 nm and 440 nm at Flex 
Station 3 (Molecular Devices, CA, USA) with 2.5  nm slit width. 
Sitagliptin, an existing DPP-IV inhibitor, was used as a positive 
control.
Starch digestion
In vitro assay of starch digestion was followed as stated earlier.[28] 
Starch solution (2 mg/ml; 100 mg in 50 ml water) was incubated 
without (control) or with E. citriodora or acarbose and 0.01% heat 
stable α-amylase (Sigma-Aldrich, St. Louis, MO, USA) from Bacillus 
leicheniformis was included. The resulting mixture was incubated 
at 80°C for 20 min. Amyloglucosidase (0.1%, Sigma-Aldrich) from 
Rhizopus mold was added to the diluted mixture and kept at 60°C 
for 30 min for further incubation. At 4°C, samples were preserved 
for the subsequent study of glucose release using the GOD/PAP 
method (Randox GL 2623).
Diffusion of glucose
Glucose absorption was assessed via cellulose ester dialysis tubing as 
previously reported.[29] The dialysis tube was loaded with 220 mM 
glucose of 2 ml volume, with or without leaf extract and the two 
ends of each tube were securely sealed and put in 0.9% NaCl solu-
tion of 45 ml. The glucose outside the tube was analysed after 24 h 
of shaking at 37°C.
Animals
A high-fat diet (Special Diet Service, Essex, UK) were fed to Sprague-
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test. On normal diet (Trouw Nutrition, Cheshire, UK), healthy age-
matched rats were preserved to use as controls. Sixteen rats were 
selected as diabetic model after assessing blood glucose level; rats 
were divided into groups including the eight age-matched lean con-
trol group (n = 8), the high-fat-fed diabetic group (n = 8) and the 
high-fat-fed treatment group (n = 8). According to previous studies, 
a single dose of extract (250 mg/5 kg, given at a volume of 5 ml/kg 
body weight) was chosen and was considered to reflect a high but ac-
ceptable level of ingestion that was not correlated with any adverse 
effects. Chronic effects of daily E. citriodora therapy in high-fat rats 
were tested at intervals over a period of 9 days without any symp-
toms of pain, influenced behaviour or any other adverse effects. In 
compliance with the UK Animals (Scientific Procedures) Act 1986 
and the EU Directive 2010/63EU, all animal studies were carried 
out. To reduce any possible animal suffering, all appropriate pre-
cautions were taken. The animal experiments were authorized by 
the local Ulster Animal Welfare and Ethical Review Body (AWERB) 
committee (01/10/2016) as well as being protected by the PIL450, 
PIL1822 and PPL 2804 UK Home Office Animal project/personal 
license numbers, approved on 06/05/2016.
Acute oral glucose tolerance and activity of 
plasma DPP-IV
Glucose tolerance test (18 mmol/kg) were performed to assess gly-
caemic control on 6 and 12 h starved obese rats plus (250 mg/5 ml/
kg E.  citriodora leaves) or minus (control) treatment as reported 
earlier.[30] Blood sample was collected at indicated time points 
(Figure 3B and C; Figure 5A and B)) for the determination of glu-
cose and plasma insulin levels using radioimmunoassay.[21] DPP-IV 
was measured by fluorometric assay.[27]
Glucose homeostasis after 9-day therapy of 
E. citriodora leaves in high-fat feeding rats
Twice-daily oral gavage with either 0.9% saline or 250 mg/5 ml/kg 
body weight E. citriodora was given to obese rats for 9 days in a raw. 
Intake of food and fluid, body weight, blood glucose and plasma 
insulin was assessed at regular intervals. After 6  days of therapy, 
glucose tolerance (18  mmol/kg) was tested. After chronic studies, 
pancreatic tissues were extracted in order to assess islet morphology 
and pancreatic insulin content.[30]
Determination of islet morphology
Tissue processing, fixation, staining and microscopic detection were 
followed as stated earlier.[31] Tissues were dissected into thin sections 
(5–8  μm) and fixed with 4% PFA followed by overnight incuba-
tion at 4°C in the presence of mouse anti-insulin (1:500) and guinea 
pig anti-glucagon (1:400) antibodies. The sections were incubated 
in the presence of Alexa Fluor 594 goat anti-mouse and Alexa Fluor 
488 goat anti-guinea pig secondary antibodies at body tempera-
ture. The slides were placed and analysed on a fluorescent Olympus 
System Microscope BX51 (Olympus instruments, UK) with TRITC 
(594 nm) or FITC (488 nm) filters following the staining of the nu-
cleus by 4′,6-diamidino-2-phenylindole. Captured (DP70camera 
adapter system) images were processed using Cell^F imaging soft-
ware to measure the islet, α-cell and β-cell area.
Purification of crude extracts
Leaf extract was re-suspended in 0.12% (v/v) Trifluoroacetic acid/
water and various contents were separated by reversed-phase high-
performance liquid chromatography using a Vydac 218TP1022 
(22 × 250 mm) preparative stainless steel 10 μm C-18 column (Grace, 
Deerfield, IL, USA), equilibrated with 0.12% (v/v) Trifluoroacetic 
acid/water at a flow rate of 5  ml/min. Using linear gradients, the 
concentration of acetonitrile within the eluting solvent was increased 
to 20% for 10 min and 70% for 40 min cycle. Five fractions that 
showed prominent insulinotropic activity on BRIN-BD11 cells, were 
screened as previously stated.[32]
Structural characterization of purified extracts
LC-MS via ESI-MS technique was employed to determine molecular 
weights of purified peaks fractions obtained on RP-HPLC. Samples 
were separated using a Kinetex 5μm F5 LC column (150 × 4.6 mm, 
Phenomenex) on a Spectra System LC (Thermo Separation Products) 
and peaks were detected with a UV detection system at 220–360 nm 
as mentioned earlier.[33]
Statistical analysis
All statistical analyses were analysed by Graph Pad prism 5 and data 
interpreted as mean ± SEM with significant limit set to P < 0.05. An 
unpaired Student’s t-test (non-parametric, with two-tailed P values) 
and one-way analysis of variance with Bonferroni post hoc tests were 
used to analyse all data where appropriate. The area under curve 
with baseline correction was plotted using the trapezoidal rules.
Results
HWEC and insulin secretion
Basal insulin secretion from clonal pancreatic β cell line, BRIN BD11 
at 5.6 and 16.7 mM glucose was 1.06 ± 0.08 and 1.52 ± 0.08 ng/106 
cells/20 min, which increased to 5.20 ± 0.2 and 7.89 ± 0.39 ng/106 
cells/20  min (P  <  0.001; Figure 1A and B) with the insulin 
secretogogues alanine (10 mM) and KCL (30 mM). Hot water ex-
tract of E. citriodora (HWEC) leaves significantly (P < 0.05–0.001) 
increased insulin release in a dose-dependent manner (1.6–5000 μg/
ml) at 5.6 mM and 16.7 mM glucose from 1.54 ± 0.15 to 4.89 ± 
0.14  ng/106 cells/20  min and 1.89  ± 0.16 to 5.87  ± 0.17  ng/106 
cells/20 min, respectively (Figure 1A and B). At 5000 μg/ml, the ex-
tract produced a maximum increase of 3.9–4.6-fold from the basal 
rate (P  <  0.001). Positive controls included insulin secretagogues, 
alanine (10 mM) and membrane depolarizing agent, KCl (30 mM). 
Importantly, extract at 1.6–200  μg/ml did not induce the release 
of the cytosolic enzyme, lactate dehydrogenase, suggesting plasma 
membrane integrity (data not shown). Hot water extract produced 
a substantial increase in insulin secretion from isolated mouse islets 
at 16.7  mM glucose (Figure 1C). Stimulation of insulin secretion 
by hot water extract was significant at concentrations of ≥50  μg/
ml (P < 0.01–0.001). An insulin secretion modulator based on glu-
cose, GLP-1 (10–6 and 10–8 M) and alanine (10 mM) was used as 
positive controls have substantially increased the release of insulin 
(P < 0.001; Figure 1C).
Eucalyptus citriodora (200  µg/ml) was incubated with 
BRIN-BD11 cells and known stimulators or inhibitors to evaluate the 
insulin releasing pathways (Figure 1E). The insulin releasing activity 
of extract was reduced (by 20%) in the presence of the K+ channel 
opener, diazoxide (300 μM) and the L-type voltage-dependent Ca2+ 
channel blocker, verapamil (50 μM) by decreasing the intracellular 
Ca2+ influx activity (Figure 1E). Insulin-releasing activity was re-
tained in the presence of a depolarizing 30  mM concentration of 
KCl. Insulin release induced by the extract was also enhanced by 
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1E). The phosphodiesterase inhibitor, IBMX and sulphonylurea, tol-
butamide were used to potentiate the production of cyclic AMP and 
secretion of insulin. In the absence of extracellular calcium, insulin 
release evoked by the extract was inhibited by 25% (Figure 1F).
HWEC and membrane depolarization and 
intracellular calcium
Plasma membrane of BRIN-BD11 cells was significantly de-
polarized with 30  mM KCl (P  <  0.001). Hot water extract of 
E.  citriodora (HWEC) also evoked membrane depolarization 
(P < 0.001; Figure 2A). Alanine induced a significant (P < 0.001) 
increase of intracellular calcium as did E.  citriodora extract 
(P < 0.001; Figure 2B).
HWEC and glucose uptake and insulin action
Glucose uptake by 3T3L1 differentiated adipocytes was studied 
using a fluorescent glucose analogue, 2-NBDG (Figure 2C–G). 
Eucalyptus citriodora extract substantially induced glucose 
Figure 1 Concentration-dependent effects of HWEC leaves on release of insulin from (A and B) clonal pancreatic β-cell line, BRIN-BD11 cells and (C) islets of 
Langerhans, (D) glycation of protein, (E) secretion of insulin with known stimulators or inhibitors and (F) plus or minus extracellular calcium from clonal β-cells. 
Values for n = 8 and 4 for insulin secretion and n = 3 for glycation of protein are mean ± SEM. *P < 0.05, **P < 0.01 and ***P < 0.001 compared to controls. 
ϕP < 0.05 and ϕϕϕP < 0.001 compared to 5.6 mM glucose with extract. ΔP < 0.05, ΔΔP < 0.01 and ΔΔΔP < 0.001 compared to respective incubation without extract. 
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uptake compared with control (P < 0.05; Figure 2E and G). This 
stimulatory effect was enhanced by 100 nM insulin (P < 0.001; 
Figure 2F and G).
HWEC and glycation of insulin
Hot water extract of E. citriodora leaves (HWEC, 200 µg/ml) sig-
nificantly inhibited the glycation of insulin by 29% (P < 0.05–0.001; 
Figure 1D) in comparison to control (220  mM glucose + insulin 
[1  mg/ml]). Aminoguanidine (44  mM; positive control) reduced 
glycation of protein by 81% (P < 0.001; Figure 1D).
HWEC and starch digestion
The established inhibitor, acarbose (1 mg/ml) significantly decreased 
enzymatic glucose liberation from starch by 85% (data not shown). 
Hot water extract substantially (P < 0.05–0.01) inhibited starch di-
gestion at concentrations >125 µg/ml, with a maximum 25% inhib-
ition at 1000 µg/ml (Figure 2H).
HWEC and glucose diffusion in vitro
Eucalyptus citriodora (mg/ml) significantly inhibited glucose dif-
fusion after 24 h of incubation (Figure 2I). A 57% inhibition was 
observed at the highest concentration (25 mg/ml) and the lowest 
effect of 10.5% was recorded at 0.2  mg/ml (P  <  0.05–0.001; 
Figure 2I).
HWEC and DPP-IV enzyme in vitro
Sitagliptin, an established drug (10 µM), inhibited by 98% the en-
zymatic liberation of AMC from DPP-IV substrate, Gly-Pro-7-
Amino-4-Methyl-Coumarin (data not shown). Extract remarkably 
inhibited DPP-IV (P  <  0.05–0.001, Figure 3A) with a maximum 
effect of 75% (P < 0.001, Figure 3A) at 5000 µg/ml.
HWEC and oral glucose tolerance and DPP-IV
A single dose of HWEC (250 mg/5 ml/kg; p.o) produced a significant 
(n = 6; P < 0.05–0.01) improvement in glucose tolerance and plasma 
insulin concentration compared to normal control rats (Figure 3B 
and C). This was associated with time-dependent inhibition of cir-
culating DPP-IV (P < 0.05–0.001; Figure 3D). The area under curve 
showed 18% (P  <  0.05) decline in DPP-IV activity (Figure 3D) 
compared with the high-fat-fed diet control rats. Positive controls, 
sitagliptin and vildagliptin (10 μmol/5 ml/kg) decreased (P < 0.001) 
enzyme activity by 70–73% (Figure 3D).
HWEC and glucose homeostasis and metabolic 
parameters in high-fat-fed rats
High-fat-fed diet rats depicted increased food, energy and fluid in-
take, body weight, blood glucose and plasma insulin levels compared 
to the lean control (Figures 4A–F and 5D and E). Twice daily oral 
gavage of HWEC significantly decreased the fluid intake and blood 
glucose level by 9% and 19%, respectively and increased plasma 
insulin by 14% from day 6 onwards compared to obese control 
Figure 2 Effects of HWEC on (A) membrane potential and (B) intracellular calcium in clonal pancreatic β cell line, BRIN BD11 and, (C, D, E, F and G) glucose up-
take, (H) starch digestion and (I) glucose diffusion in vitro. Changes of fluorescence intensity in differentiated 3T3L1 adipocyte incubated with HWEC (E) minus 
or (F) plus 100 nM insulin. The ×10 magnification was used to take the images. Values for n = 6 for membrane potential and intracellular calcium, n = 4 for uptake 
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Figure 4 Effects of 9 days treatment of twice daily oral gavage of HWEC on (A) food intake, (B) energy intake, (C) fluid intake, (D) body weight, (E) blood glucose, 
(F) plasma insulin and (G) DPP-IV in high-fat-fed rats. Parameters were assessed twice a day, before and after oral gavage of E. citriodora leaves (250 mg/5 ml/kg, 
body weight). Values for n = 8 rats are mean ± SEM. *P < 0.05, **P < 0.01 and ***P < 0.001 compared with lean control rats. ΔP < 0.05, ΔΔP < 0.01 and ΔΔΔP < 0.001 
compared to obese control rats at the following time points.
Figure 3 Effects of HWEC on (A) DPP-IV enzyme in vitro, (B) glucose tolerance, (C) plasma insulin and (D) plasma DPP-IV in high-fat-fed rats. In vivo parameters 
were evaluated before and after oral gavage of glucose alone (18 mmol/kg body weight, control) or with E. citriodora extract (250 mg/5 ml/kg body weight). 
Values for n = 3 for in vitro DPP-IV enzyme activity and n = 6 for parameters in vivo are mean ± SEM. *P < 0.05, **P < 0.01 and ***P < 0.001, compared to lean 
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rats (P  <  0.05–0.001; Figures 4C,E,F and 5D and E). No signifi-
cant changes were observed in food, energy intake and body weight 
(Figure 4A,B,D). Hot water extract of E. citriodora also decreased 
plasma DPP-IV level in obese rats (P < 0.05) by 21% (Figures 4G 
and 5F).
HWEC and chronic glucose tolerance and 
plasma DPP-IV
HWEC (250 mg/5 ml/kg; p.o.) substantially (P  < 0.05–0.01) en-
hanced glucose tolerance (at 30, 60, 120 and 180 min) after 6 days 
of therapy to high-fat-fed rats (Figure 5A). Increased plasma in-
sulin concentrations (Figure 5B) and a 15–17% decrease in plasma 
DPP-IV enzyme activity were also consistent with this effect 
(P < 0.05; Figure 5C).
HWEC and pancreatic insulin content and islet size 
distribution and area
No significant changes in the pancreas weights of treated or un-
treated high-fat-fed or normal control rats were observed (Figure 
5G). However, pancreatic insulin content significantly (54%; 
P  <  0.001) increased in high-fat-fed rats compared to lean rats. 
Hot water extract of E.  citriodora significantly (P  <  0.01) de-
creased pancreatic insulin compared to high-fat-fed control rats 
(Figure 5H).
Figure 6 provides comparative pictures of pancreatic tissues of 
normal control (A), high-fat fed (B) and high-fat fed receiving HWEC 
(250 mg/5 ml/kg) (C), respectively. Eucalyptus citriodora resulted in 
a significant decrease in islets number per mm2 in pancreas (Figure 
6J). A significant (P < 0.001) decrease in islet area was also observed 
(P < 0.05; Figure 6D), but there were no changes in β-cell and α-cell 
areas compared to obese rats (Figure 6E and F). High-fat-fed rats, on 
the other hand, showed substantial increases in islet, β-cell and α-cell 
areas compared to lean control rats (Figure 6D,E,F). The numbers 
of large and medium sized islets were greater in high-fat-fed groups 
compared to lean controls (Figure 6G). The percentage of β-cells was 
also increased in high-fat-fed groups, whereas α-cell percentage was 
decreased (Figure 6H and I).
Insulin-releasing activity and structural 
identification of purified extract
RP-HPLC and LC-MS were used to isolate and characterize 
phytoconstituents from the crude leaf extract (Figures 7A and 8A–
E). Five major fractions of E.  citriodora were assayed for insulin-
releasing activity using BRIN-BD11 cells (Figure 7B; peak samples 
(P-1 to P-5). It was observed that P-1 to P-5 greatly (P  <  0.001) 
induced insulin secretion, but P-1 showed cytotoxicity assessed by 
cellular leakage of LDH (data not shown). Positive control, alanine 
(10 mM) was used (Figure 7B). Peak fractions of interest were fur-
ther analysed using LC-MS for determination of molecular mass 
Figure 5 Long-term effects of twice daily oral gavage of HWEC leaves on (A) glucose tolerance, (B) plasma insulin and (C) plasma DPP-IV on day 6 and (D) blood 
glucose, (E) plasma insulin, (F) plasma DPP-IV, (G) pancreas weight and (H) pancreatic insulin content on day 9 in high-fat-fed rats. Parameters after 6 or 9 days of 
therapy with twice daily oral gavage of E. citriodora leaf (250 mg/5 ml/kg body weight) were measured. Values for n = 8 rats are mean ± SEM. *P < 0.05, **P < 0.01 
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(Figure 8A–E). The molecular masses obtained for the three com-
pounds corresponded with the previously isolated phytochemicals, 
quercitrin,[34] isoquercitrin[35] and rhodomyrtosone E.[17] The chem-
ical structures and molecular masses of these three compounds are 
shown in Figure 9A–C.
Discussion
Type 2 diabetes and obesity are chronic disorders that are intricately 
linked such that body mass index is a useful marker for manifest-
ation of insulin resistance and glucose tolerance.[2] Obesity is also as-
sociated with elevations of circulating free fatty acids, cytokines and 
other mediators of cellular damage that promote insulin resistance 
and impaired β-cell function on the pathway to diabetes develop-
ment.[36] Previous studies have reported that E. citriodora possesses 
properties useful for the treatment of diabetes in folk medicine, but 
the mechanisms mediating such actions are unknown.[10, 17] This 
study was designed to investigate possible insulinotropic effects and 
other antihyperglycaemic actions of E. citriodora.
Eucalyptus citriodora leaves stimulated both glucose and 
concentration-dependent insulin release from BRIN-BD11 cells 
and isolated mouse pancreatic islets. To understand the molecular 
mechanism involved, the effects of non-toxic concentrations of 
E. citriodora were assessed in the presence or absence of modula-
tors of β-cell function. This revealed inhibitory effects of diazoxide, 
verapamil and extracellular Ca2+ depletion, suggesting involve-
ment of KATP channels, L-type calcium channels and Ca
2+ influx in 
the insulin secretory actions Consistent with this view, the extract 
depolarized β-cell plasma membrane and increased intracellular 
Ca2+. Since stimulatory effects persisted in β-cells depolarized by 
the sulphonylurea KATP channel blocker, tolbutamide or 30  mM 
KCl, additional actions must be triggered through KATP-independent 
pathways involving PI3 (phosphatidylinositol) or adenylate cyclase/
cAMP.[37] Indeed, insulinotropic effects of the extract were sub-
stantially potentiated by the phosphodiesterase inhibitor, IBMX. 
Interestingly, previous studies revealed the potential of E. citriodora 
in asthma as adjunct therapy,[38] with benefits ascribed to the eleva-
tion of cAMP in lung tissues thereby blocking replication in bron-
chial smooth muscle cells and promoting airway relaxation.[39]
Insulin primarily targets skeletal muscle and adipose tissue for 
post-prandial glucose regulation and defects in the signal trans-
duction pathway in these cells with decreased GLUT-4 transloca-
tion is an important contributor to insulin resistance.[40, 41] In this 
study, effects of E. citriodora on glucose uptake were investigated 
using 3T3L1 differentiated adipocyte cells. The extract significantly 
stimulated glucose transport in the absence and presence of in-
sulin. Previous studies have reported that phytomolecules such as 
gallic acid, egallic acid, berberine, quercetin and isoquercitrin[42, 43] 
may increase the glucose uptake by modulating AMPK activity. As 
E. citriodora extract has been reported to contain polyphenols like 
gallic acid and ellagic acid, these components might trigger this and 
other signalling pathways to improve glucose uptake.
Protein glycation is a physiological process that plays a significant 
role in the pathophysiology of diabetes.[44] The extract significantly 
inhibited insulin glycation in dose-dependent manner. Previous 
studies reported E. citriodora as potential antioxidant plant,[45] which 
may explain its ability to ameliorate protein damage induced by oxi-
dative stress and inhibit insulin glycation.[46] Glycation of insulin 
Figure 6 Effects of 9 days treatment of HWEC on islet morphology in high-fat-fed rats. Illustrative pictures of (A) lean control, (B) high-fat-fed control and (C) 
high-fat fed plus hot water extract of E. citriodora (250 mg/5 ml/kg) in rats presenting insulin in red, glucagon in green and DAPI in blue, (D) islet area, (E) α-cell 
area, (F) β-cell area, (G) islet size distribution, (H) percentage of α-cell, (I) percentage of β-cell and (J) number of islets (per mm2), respectively. Values for n = 8 
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results in an approximately 20% decrease in biological activity,[47] 
but significance of inhibition of protein glycation generally extends 
to countering adverse modification of functional and structural pro-
teins involved in β-cell dysfunction and diabetic complications.
A useful approach to management of post-prandial hyper-
glycaemia is inhibition of the digestive enzymes, α-amylase and 
α-glucosidase. This slows entry of glucose into the blood, thereby 
moderating the glycaemic excursion and demands on β-cells 
following feeding. E. citriodora extract inhibited starch breakdown 
in a concentration-dependent manner which might reflect presence 
of flavonoids which have been reported to inhibit activity of these 
enzymes.[48] Decrease of gastrointestinal absorption and glucose dif-
fusion is another important means of moderating glucose response 
to feeding.[29] In this study, a simple in vitro dialysis method was used 
to mimic the gut barrier and investigate the effects of E. citriodora 
on glucose diffusion. Extracts of E.  citriodora exerted significant 
Figure 7 Representative (A) HPLC profile and (B) insulin-releasing effects of peak samples (1–5) of E. citriodora leaves. Crude extract was chromatographed at 
a flow rate of 1.0 ml/min on a (10 × 250 mm) semi-preparative 5 μm C-18 column (Phenomenex, UK). Using linear gradients of acetonitrile (0–20% up to 10 min, 
20–70% up to 40 min), the concentration of the eluting solvent was increased. Compounds were detected by measurement of absorbance at 254–360 nm. Peak 
fractions 1–5 were collected and insulin-releasing activity assessed using BRIN-BD11 cells. Values for n = 8 rats are mean ± SEM for insulin release. *P < 0.05, 
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concentration-dependent inhibitory effects on glucose movement 
into an external solution through dialysis membrane. Decreased 
hyperglycaemia of STZ-induced diabetic animals induced by dietary 
supplements of E.  citriodora was attributed to the modulation of 
glucose movement from the gut.[38] Several lines of evidence also sug-
gest that the viscosity and presence of soluble dietary fibres retard 
glucose transport by slowing transit time and modifying both the 
digestive and absorptive processes.[29, 49]
Sprague-Dawley rats fed with high-fat diet replicate obesity and 
metabolic disorders such as tolerance to insulin reminiscent of type 2 
diabetes.[50, 51] In an acute in vivo experiment, E. citriodora extract sig-
nificantly improved glucose tolerance and plasma insulin responses of 
obese rats. These results were reinforced by results of further long-term 
studies in obese rats that showed remarkable improvements induced 
in blood glucose, glucose tolerance and circulating insulin compared 
with obese control rats. As well as improving β-cell function directly, 
the extract also inhibited activity of DPP-IV both in vitro and in vivo. 
This enzyme deactivates incretin hormones by cleavage of N-terminal 
that leads to generation GLP-1 (9–36) and GIP (3–42).[52] Accordingly, 
E. citriodora may also indirectly improve β-cell function by increasing 
the half-life and stimulatory effects of endogenous GLP-1 and GIP. 
Interestingly, previous studies have reported that various plants and 
constituent phytochemicals possess DPP-IV inhibitory activity.[53, 54]
Insulin resistance due to consumption of a high-fat-fed diet, re-
duces insulin-mediated glucose uptake by the peripheral tissues, 
causes unrestrained hepatic glucose output and thereby increases en-
dogenous insulin demand.[55] This causes β-cells to hypersecrete and 
expand β-cell mass due to proliferative activity.[56] In this study, high-
fat-fed rats showed a significant increase in islet, β-cell and α-cell 
areas which were partly normalized by E.  citriodora. Significant 
changes were noted in both the area and total number of islets 
per mm2. The increase in pancreatic insulin content observed with 
E. citriodora might therefore be mediated by modulation of β-cells 
mass as well as direct actions and possible secondary effects medi-
ated by endogenous GLP-1 and GIP.[22]
Eucalyptus citriodora extract was analysed for the identification 
and characterization of active compounds targeting insulin secreting 
β-cells. Fractions were collected from the RP-HPLC and five major 
peaks were tested using BRIN-BD11 cells. All peaks significantly 
stimulated insulin release (P < 0.001), but P-1 was associated with 
LDH release and cellular toxicity (data not shown). This evaluation 
of bioactivity was followed by LCMS to identify molecular mass 
of the active RP-HPLC fractions. Molecular masses of three com-
pounds isolated corresponded with those of quercitrin, isoquercitrin 
and rhodomyrtosone E.[17, 34, 35] This result is in line with previous 
findings reporting that E.  citriodora contained isoquercitrin and 
rhodomyrtosone E.[17] No previous studies have validated quercitrin 
as a phytoconstituents of E. citriodora, but others have noted that 
quercitrin is a glycoside derived from quercetin and deoxy sugar 
rhamnose.[57] The study by Wang et al.[17] is particularly noteworthy 
because, as well as rhodomyrtosone E, it reported 12 other com-
pounds in E. citriodora including seven triterpenes, four flavonoids 
and one polyphenolic compound, gallic acid. Several of these may 
contribute to antidiabetic activity.[58]
Figure 8 Molecular masses of insulin-releasing peak samples of E. citriodora leaves by LC-MS analysis. A Kinetex 5μm F5 LC column ((150 × 4.6 mm; Phenomenex) 
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Conclusion
This study has shown that E. citriodora leaf extract exerts significant 
antidiabetic effects in vitro and in high-fat-fed rats due to a variety of 
pancreatic and extra pancreatic actions. These include stimulation of 
both the secretion and action of insulin as well as inhibition of DPP-IV 
activity, starch digestion, glucose diffusion and protein glycation. 
Phytochemicals acting at level of the β-cells are likely to include 
quercitrin, isoquercitrin and rhodomyrtosone E, possibly with their 
metabolites Further investigations are warranted to fully characterize 
the benefits of E. citriodora and its phytoconstituents for the potential 
prevention, treatment and management of type 2 diabetes in man.
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